South Korean Ministry of Health's Lee Hae-hee On Partnership With AstraZeneca To Bolster Domestic Firms' Global Aspirations: An Interview With PharmAsia News.
This article was originally published in PharmAsia News
Executive Summary
SEOUL - AstraZeneca Plc. signed a memorandum of understanding with South Korea's Ministry of Health and Welfare April 4 to commit to an R&D investment of KRW 80 billion ($73.48 million) in Korea through the next five years. The company also agreed to provide training and information exchanges to Korea's pharma industry, which is looking for inroads into foreign markets. The MOU is a follow-up to an MOU signed between the two parties in 2006. Lee Hae-hee, healthcare R&D assistant director at South Korea's Ministry of Health and Welfare, discussed the deal - announced in early April - with PharmAsia News on the sidelines of Medical Korea.
You may also be interested in...
Merck Signs Wide-Ranging MOU To Help Beef Up Korea's Global R&D Capabilities
SEOUL - Merck & Co. Inc. has signed a memorandum of understanding with South Korea to invest KRW 210 billion ($192.9 million) in the country for research and development of new drugs, including manpower exchanges, Korea's Ministry of Health and Welfare said
Novartis Signs MOU To Invest $100 Million In R&D, Exchanges With Korean Scientists By 2013
SEOUL - Novartis signed a memorandum of understanding with Korea's Ministry for Health, Welfare and Family Affairs to invest $100 million (KRW 125 billion) over the next five years in the research and development of new drugs, scientific exchanges and collaboration in the life sciences
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).